Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 127

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 127
---
 intended purpose of providing relief from chronic conditions including osteoarthritis. This second potential
product is described by the third family of patents derived from WO 2011/07399, which was filed December 16, 2010. Patents from this
family are nominally due to expire in December 2030 and include patents Nos. US 8,846,020, EP 2513294, CN 102762715 and IL 220343, which
are detailed in the table below.

GelrinP derived from WO 2014/207749
filed June 24, 2014 claims an injectable curable paste that can be shaped to fill defects requiring treatment. The family of patent applications
derived from WO 2014/207749 includes patents Nos. US 10,434,215, EP 3013377 and CN 105407933, which are detailed in the table below.

A patent derived from WO
2008/126092, patent No. US 9,624,259, that was filed April 16, 2008, claims conjugates of the serum protein albumin with PEG. This patent
may be useful to supplement the protection of GelrinC which may contain albumin as well as fibrinogen.

Patents derived from or related to WO 2015/052708 filed on January 24, 2014 claim an apparatus or method for treatment of cavities in a human body. The patent applications derived include patents Nos. US 9,895,519, US 9,872,705, EP 2874546(validated in Germany, France
and the United Kingdom), CN 106232023 and IL 235270, which are detailed in the table below.

The patent portfolio of the
Company includes granted patents that cover the products currently in development and additional families of patents that may provide
supplementary protection for those products and further products.

<div align='center'>78</div>

Patents

As of April 7, 2025, our exclusively owned patent portfolio includes thirty-four (34) issued patents, of which eight (8) are U.S. patents and twenty-six (26) are foreign patents, with eighteen (18) of the twenty-six (26) foreign patents being nationally validated in certain European extension/validation states). In addition, one U.S. patent application and three patent applications are pending. The claims of the owned patents and patent applications below are directed